New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and in press at The Lancet shows that trevogrumab, which inhibits a protein that negatively regulates muscle mass, can reduce lean mass loss during semaglutide treatment by 50% compared with semaglutide and placebo.
from Medical Xpress - latest medical and health news stories https://ift.tt/5kQC2X3
